Literature DB >> 6795300

The vascular bed as the primary target in the destruction of skin grafts by antiserum. II. Loss of sensitivity to antiserum in long-term xenografts of skin.

S V Jooste, R B Colvin, H J Winn.   

Abstract

Rat skin that survives for long periods of time on immunosuppressed mice becomes resistant to anti-graft serum and remains so for as long as it survives. When long-standing grafts are removed and placed on new immunosuppressed mice, they remain resistant to antiserum for as long as they survive. The acquired resistance to antiserum seems, therefore, to be due to changes in the grafts rather than to changes in their hosts. Furthermore, it was found that the acquisition of resistance is correlated with replacement of graft endothelium by host cells, as demonstrated by the use of immunofluorescent techniques in conjunction with mouse anti-rat serum and rat anti-mouse serum. Evidently, humoral antibodies are able to cause acute damage to skin grafts, and presumably to grafts to other organized tissues, only if they react with antigens of graft endothelium. Long-term grafts that are retransplanted to their original donors or to rats syngeneic with those donors are in most cases rejected, whereas 14-d-old grafts similarly regrafted are in no case rejected. Apparently, the responses of the secondary recipients to the mouse endothelial antigens in long-term grafts lead to destruction of the entire grafts. When long-standing rat skin xenografts are removed and placed on untreated mice syngeneic with the primary hosts, they are in every case rejected, although they survive slightly longer than skin taken directly from rat donors. Rejection is accompanied by a mononuclear infiltrate and is qualitatively indistinguishable from the rejection of freshly prepared rat skin. Clearly, sensitized cells are more efficient than humoral antibody in destroying grafted tissues.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6795300      PMCID: PMC2186507          DOI: 10.1084/jem.154.5.1332

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  7 in total

1.  Acute destruction by humoral antibody of rat skin grafted to mice.

Authors:  C A Baldamus; I F McKenzie; H J Winn; P S Russell
Journal:  J Immunol       Date:  1973-06       Impact factor: 5.422

2.  Destruction of rat skin grafts by humoral antibody.

Authors:  S V Jooste; H J Winn; P S Russell
Journal:  Transplant Proc       Date:  1973-03       Impact factor: 1.066

3.  In vivo methods for the assessment of antibody-mediated tumor immunity.

Authors:  H J Winn
Journal:  Natl Cancer Inst Monogr       Date:  1972-12

4.  Acute destruction of rat skin grafts by alloantisera.

Authors:  S V Jooste; H J Winn
Journal:  J Immunol       Date:  1975-03       Impact factor: 5.422

5.  Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression.

Authors:  H F Dvorak; A M Dvorak; E J Manseau; L Wiberg; W H Churchill
Journal:  J Natl Cancer Inst       Date:  1979-06       Impact factor: 13.506

6.  Sensitivity of long-standing xenografts of rat hearts to humoral antibodies.

Authors:  J F Burdick; P S Russell; H J Winn
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

7.  The vascular bed as the primary target in the destruction of skin grafts by antiserum. I. Resistance of freshly placed xenografts of skin to antiserum.

Authors:  S V Jooste; R B Colvin; W D Soper; H J Winn
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

  7 in total
  10 in total

Review 1.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

2.  Localization of hematopoietic progenitor cells in tissue with the anti-My-10 monoclonal antibody.

Authors:  W E Beschorner; C I Civin; L C Strauss
Journal:  Am J Pathol       Date:  1985-04       Impact factor: 4.307

3.  Selective transplantation. An emerging concept.

Authors:  P S Russell
Journal:  Ann Surg       Date:  1985-03       Impact factor: 12.969

4.  Monokine induced by interferon-gamma (MIG/CXCL9) is derived from both donor and recipient sources during rejection of class II major histocompatibility complex disparate skin allografts.

Authors:  Michael B Auerbach; Naohiko Shimoda; Hiroyuki Amano; Joshua M Rosenblum; Danielle D Kish; Joshua M Farber; Robert L Fairchild
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

5.  The vascular bed as the primary target in the destruction of skin grafts by antiserum. I. Resistance of freshly placed xenografts of skin to antiserum.

Authors:  S V Jooste; R B Colvin; W D Soper; H J Winn
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

Review 6.  Role of complement and NK cells in antibody mediated rejection.

Authors:  Takurin Akiyoshi; Tsutomu Hirohashi; Alessandro Alessandrini; Catherine M Chase; Evan A Farkash; R Neal Smith; Joren C Madsen; Paul S Russell; Robert B Colvin
Journal:  Hum Immunol       Date:  2012-07-28       Impact factor: 2.850

7.  Immunologically nonspecific mechanisms of tissue destruction in the rejection of skin grafts.

Authors:  D P Doody; K S Stenger; H J Winn
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

8.  Haptens can serve as surrogate transplantation antigens in a manner that demonstrates H-2 restriction of graft rejection.

Authors:  J W Streilein; P R Bergstresser
Journal:  J Exp Med       Date:  1983-04-01       Impact factor: 14.307

Review 9.  The Impact of Inflammation on the Immune Responses to Transplantation: Tolerance or Rejection?

Authors:  Mepur H Ravindranath; Fatiha El Hilali; Edward J Filippone
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

10.  Fibronectin is produced by blood vessels in response to injury.

Authors:  R A Clark; J H Quinn; H J Winn; J M Lanigan; P Dellepella; R B Colvin
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.